Amgen's Aranesp disappoints in heart failure PMLiVE The failure of RED-HF to show any benefit in heart failure patients is reminiscent of the results of an earlier study called TREAT, which also showed no benefit Aranesp on death and cardiovascular endpoints in diabetic patients with chronic kidney ... Aranesp Fails in RED-HF Trial |
